Swedish orthobiologics company Bonesupport Holding AB (STO:BONEX) on Tuesday announced positive results from a clinical study evaluating CERAMENT G in single-stage revision surgery for periprosthetic joint infection (PJI) of the hip.

The prospective study at Charité - Universitätsmedizin Berlin involved 20 patients undergoing implant removal, debridement, and defect augmentation with CERAMENT G, followed by cementless revision arthroplasty.

Over a 24-month follow-up, none of the patients experienced reinfection, and significant improvements were reported in patient outcomes, including Harris Hip Score, EQ-5D-5L, and Pain Visual Analogue Scale (VAS). Current standards typically involve a two-stage procedure, with reinfection rates of approximately 30% within two years according to the German Arthroplasty Registry.

The results, presented at the European Bone and Joint Infection Society annual meeting, suggest that CERAMENT G may provide a safer, single-stage alternative for managing hip PJI. The full study (CeraHip) is expected to be published in autumn 2025.